top of page


Boehringer Ingelheim signs Sino Biopharmaceutical oncology deal worth up to $7.36 billion
Boehringer Ingelheim has entered a major oncology partnership with Sino Biopharmaceutical covering six preclinical antibody-drug conjugate and T-cell engager programmes, with potential payments reaching approximately $7.36 billion.

nuaxia
Nov 52 min read


STADA and SBP Group partner on Keytruda biosimilar and up to three additional biosimilar programmes
STADA and SBP Group have launched a strategic biosimilars partnership beginning with a proposed Keytruda biosimilar and providing a framework for up to three additional programmes.

nuaxia
Sep 292 min read
bottom of page